Biotech entity
They are better corroborated than the beat average, carrying 21.6 original sources each against 3.9 for the same window. Negative sentiment reaches 0% here, compared with 17% across the 556-story beat baseline for the same window. Of the tracked stories, 3 of 7 also mention Codexis, the most common co-covered peer.
Last mentioned: 3d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 71 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
They are better corroborated than the beat average, carrying 21.6 original sources each against 3.9 for the same window. Negative sentiment reaches 0% here, compared with 17% across the 556-story beat baseline for the same window. Of the tracked stories, 3 of 7 also mention Codexis, the most common co-covered peer. Across a 148-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 2. pharma accounts for 4 of the 7 tracked stories, while 2 other categories carry the remainder. At 7, the average consequence score sits above the same-window beat average of 6.2. This profile follows 7 Biotech stories mentioning Merck across the period from February 19, 2026 to July 16, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 556 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
Merck and Mayo Clinic have entered a multi-year research and development collaboration to leverage artificial intelligence for drug discovery and personalized patient care. The partnership integrates Merck's pharmaceutical expertise with Mayo Clinic's clinical data and AI capabilities to accelerate the development of targeted therapies.
Source: Yahoo Finance · Mayo Clinic News Network
Merck is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
